Quick Answer
PharmaCyte Biotech, Inc. reported Net Income Loss of $30.66 million for the year ending 2025.
- PharmaCyte Biotech, Inc. showed an increase of +9,085.0% in Net Income Loss from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), PharmaCyte Biotech, Inc.'s Net Income Loss has grown by 2,293.3%.
- Historical annual values: Fiscal year 2025: $30.66 million | Fiscal year 2024: $333.8 thousand | Fiscal year 2023: -$4.32 million | Fiscal year 2022: -$4.24 million | Fiscal year 2021: -$3.55 million | Fiscal year 2020: -$3.83 million | Fiscal year 2019: -$4.07 million | Fiscal year 2018: -$6.83 million | Fiscal year 2017: -$4.44 million | Fiscal year 2016: -$6.06 million | Fiscal year 2015: -$9.93 million | Fiscal year 2014: -$27.25 million | Fiscal year 2013: -$1.60 million | Fiscal year 2012: -$1.90 million | Fiscal year 2011: -$1.40 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: